Kliniken & Institute ... Kliniken Neurologische Klinik ... Neurologie und... Forschung Publications


Publications 2017 (PDF)

Publications 2016 (PDF)

Publications 2015 (PDF)

We have published a series of major papers improving our understanding of neurological diseases. In 2015/2016, our department published more than 300 papers and top publications reaching the 3rd place (together with the department of Pharmacology) in the Heidelberg University Hospital publication ranking. Our most significant discoveries in 2015 and 2016 include:

  • Effect of Conscious Sedation vs General Anesthesia on Early Neurological Improvement Among Patients With Ischemic Stroke Undergoing Endovascular Thrombectomy: A Randomized Clinical Trial. Schönenberger et al. JAMA 2016
  • Safety of Endovascular Thrombectomy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants. Purrucker et al. Stroke 2016
  • Early Clinical and Radiological Course, Management, and Outcome of Intracerebarl Hemorrhage Related to New Oral Anticoagulants. Purrucker et al. JAMA Neurol. 2016
  • Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Baumert et al. Lancet Oncol 2016
  • Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Reijneveldt et al. Lancet Oncol 2016
  • Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio. Chinot et al. Neuro Oncol 2016
  • Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082). Wick et al. Clin Cancer Res 2016
  • Slowing down glioblastoma progression in mice by running or the anti-malarial drug dihydroartemisinin? Induction of oxidative stress in murine glioblastoma therapy. Lemke  et al. Oncotarget. 2016
  • A phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. Brandes et al.  Neuro Oncol. 2016
  • Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma. Ilhan-Mutlu et al. Mol Cancer Ther. 2016
  • Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. Kernan et al. N Engl J Med. 2016
  • Association between age and risk of stroke or death from carotid endarterectomy and carotid stenting: a meta-analysis of pooled patient data from four randomised trials. Howard et al. Lancet 2016
  • Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Wick et al. Neuro Oncol 2016
  • Fresh frozen plasma versus prothrombin complex concentrate in patients with intracrnial haemorrhage related to vitamin Kantagonists (INCH): a ramdomised trial. Steiner et al. Lancet Neurol 2016
  • Brain tumour cells interconnect to a functional and resistant network. Osswald et al. Nature 2015
  • Proximity ligation assay evaluates IDH1R132H presentation in gliomas. Bunse et al. Clin Invest 2015
  • Diagnostic work-up for detection of paroxysmal atrial fibrillation after acute ischemic stroke: cross-sectional survey on German stroke units. Rizos et al. Stroke 2015
  • Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma. Kessler et al. Oncotarget 2015
  • IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. Kickingereder et al. Sci Reports 2015
  • Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma. Taphoorn et al. J Clin Oncol 2015